Regulatory updates and approvals

October brought important developments in regulatory approvals and pharmacovigilance, reflecting the continued focus on medicine safety, treatment effectiveness and patient access.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Icotyde (icotrokinra hydrochloride), a new once-daily oral treatment for adults and adolescents aged 12 and over, weighing at least 40kg, with moderate-to-severe plaque psoriasis who are eligible for systemic treatment.

Supported by four Phase 3 clinical trials involving approximately 2,500 participants, the treatment demonstrated efficacy compared with placebo at week 16. Icotyde selectively blocks the IL-23 receptor, helping to reduce inflammatory and immune responses associated with psoriasis.

Meanwhile, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) continued monitoring medicine safety through the evaluation of emerging signals.

Notable safety discussions included potential interactions between cefpodoxime and proton pump inhibitors, which may reduce antibiotic effectiveness, and between lithium and GLP-1 receptor agonists, which could lead to increased lithium levels.

Additional assessments examined batch-associated hypersensitivity reactions involving human normal immunoglobulin products and emerging safety information concerning antiviral treatments for critically ill influenza patients.

A further regulatory review was initiated for the combination of melitracen hydrochloride and flupentixol hydrochloride, following a referral from Belgium concerning its benefit-risk balance.

Together, these developments reinforce the importance of ongoing pharmacovigilance, regulatory oversight and proactive risk management throughout the medicine lifecycle.

Advances in research and innovative therapies

Clinical research continued to deliver encouraging developments throughout October, particularly in oncology, neurology, dermatology and rare diseases.

In multiple sclerosis, Novartis presented positive results from two Phase 3 trials evaluating remibrutinib, an oral BTK inhibitor for relapsing multiple sclerosis. Over 24 months, more than 92% of patients remained free from disease progression, while the treatment demonstrated reduced relapse rates and a favourable safety profile.

Oncology research also reported significant progress. Roche announced positive Phase 3 KRASCENDO 1 results for divarasib, an investigational next-generation KRAS G12C inhibitor for previously treated non-small cell lung cancer.

The study demonstrated a 44% reduction in the risk of death compared with approved standard-of-care treatments, with median overall survival reaching approximately 18 months versus 12 months in the control group. The findings highlight the potential of next-generation targeted therapies to improve outcomes for patients with difficult-to-treat cancers.

Dermatology was another area of significant research activity.

AbbVie reported continued facial and total-body repigmentation through week 76 in Phase 3 studies evaluating Rinvoq (upadacitinib) for non-segmental vitiligo. Pfizer also announced positive Phase 3 results for Litfulo (ritlecitinib), demonstrating improvements in facial and total-body repigmentation compared with placebo.

Meanwhile, MSD presented encouraging Phase 2b results for tulisokibart, an investigational anti-TL1A antibody for moderate-to-severe hidradenitis suppurativa. The study met its primary endpoint, supporting plans to advance the treatment into Phase 3 development.

Rare disease research also gained momentum through a collaboration between DEBRA Research and Topadur Pharma to investigate potential therapies for dystrophic epidermolysis bullosa. The programme will evaluate compounds targeting impaired wound healing and fibrosis, with the aim of addressing underlying disease complications rather than symptom management alone.

These developments demonstrate the industry’s increasing focus on targeted treatments, disease modification and improving long-term patient outcomes.

Vaccine development and emerging treatment approaches

October’s research highlighted new opportunities to improve disease prevention and expand treatment options through innovative technologies.

The MHRA and GSK Vaccines Institute for Global Health published promising research into a potential needle-free vaccine for Group A Streptococcus (Strep A).

Using Generalised Modules for Membrane Antigens (GMMA) technology, researchers demonstrated immune responses following vaccine delivery through the nose or under the tongue.

With more than 600 million Strep A infections and over 500,000 associated deaths estimated globally each year, the findings represent a potentially important step towards developing more accessible vaccination strategies.

The research also highlights opportunities to reduce antibiotic use and support global efforts to tackle antimicrobial resistance.

Elsewhere, emerging approaches to paediatric epilepsy management emphasised the importance of moving beyond seizure suppression towards therapies addressing underlying disease mechanisms.

Experts highlighted the potential of genomic testing, artificial intelligence and personalised treatment strategies to improve diagnosis and care for children with complex epilepsy.

Another discussion explored neuromodulation as a potential non-pharmacological treatment option for migraines during pregnancy. Technologies such as Remote Electrical Neuromodulation and External Trigeminal Nerve Stimulation may provide alternatives for patients seeking to minimise systemic medication exposure, although further pregnancy-specific safety research is needed.

Together, these developments illustrate how innovation is expanding beyond conventional drug development to include new delivery methods, personalised care and technology-enabled treatment approaches.

Industry partnerships, investments and acquisitions

Strategic investment and collaboration remained prominent themes throughout October, with pharmaceutical companies expanding research capabilities and strengthening their portfolios.

AstraZeneca opened a new global strategic research and development centre in Kendall Square, Cambridge, Massachusetts.

The 570,000-square-foot facility will bring together nearly 2,000 researchers and scientists, supporting innovation across oncology, cell therapy, chronic diseases and rare conditions.

Featuring advanced robotics, laboratory automation and artificial intelligence technologies, the centre forms part of AstraZeneca’s wider $50 billion investment commitment in the United States.

In the rare disease sector, Shionogi announced an agreement to acquire IntraBio in a deal valued at approximately $2 billion.

The proposed acquisition would add Aqneursa (levacetylleucine) and additional rare disease expertise to Shionogi’s portfolio, strengthening its capabilities in neurodegenerative conditions.

The agreement would also expand Shionogi’s development pipeline across conditions including Pompe disease, Fragile X syndrome and other rare neurological disorders.

These investments demonstrate the continued importance of strategic partnerships, specialist expertise and research infrastructure in accelerating pharmaceutical innovation.

Healthcare initiatives and patient-centred innovation

Patient involvement and healthcare accessibility remained important themes in October, with growing recognition that successful innovation requires a deeper understanding of individual patient experiences.

One article examined the importance of preparing patients and patient organisations for meaningful participation in European Health Technology Assessment (HTA) processes.

While evolving HTA frameworks create opportunities for patients to contribute to clinical assessments and scientific consultations, complex terminology, limited resources and unfamiliar procedures can create barriers to effective participation.

The discussion emphasised the importance of early engagement, accessible information and practical support to ensure patients can contribute their lived experiences authentically.

Another analysis explored the increasing role of private healthcare in the UK and its implications for pharmaceutical companies.

As patients increasingly access treatment through private medical insurance and self-pay pathways, healthcare communications must evolve to address different patient journeys, decision-makers and information requirements.

The article highlighted the growing influence of specialist nurses, pharmacists, insurers and employers in shaping access to healthcare services.

These perspectives reinforce the importance of developing patient-centred strategies that reflect the changing healthcare landscape and support informed decision-making.

Healthcare communications, regulatory strategy and commercial innovation

October’s newsletter also explored the evolving relationship between scientific innovation, regulatory strategy and effective healthcare communications.

ANTHEM, part of Resonant Group, launched Healthy Influence, a science-led methodology designed to improve the visibility and impact of healthcare information.

Drawing on behavioural and social science, the approach focuses on attention, emotion and trust to help credible health messages reach patients, healthcare professionals and policymakers more effectively.

The initiative reflects the growing need for healthcare organisations to address misinformation, information overload and declining trust through more meaningful engagement.

Regulatory complexity was another important focus.

An industry analysis examined how changing global requirements and regional regulatory differences are creating challenges for pharmaceutical companies managing clinical development programmes.

The article highlighted the potential financial consequences of clinical trial delays and the increasing importance of specialist regulatory expertise and flexible functional service provider models.

Meanwhile, discussions around the UK’s life sciences ambitions emphasised the importance of stronger collaboration between pharmaceutical companies, the NHS and policymakers.

The central message was that scientific progress must be accompanied by earlier engagement, clearer communication of value and shared responsibility for implementing healthcare innovation.

Medical education also featured prominently, with Medscape Education highlighting its initiatives at the European Society for Medical Oncology (ESMO) 2026 Congress.

Through precision oncology education, scientific symposia and evidence-based learning programmes, the organisation continues to support healthcare professionals in translating complex clinical developments into informed treatment decisions.

Together, these developments underline the importance of combining scientific expertise, strategic communication and regulatory understanding to achieve meaningful healthcare outcomes.

Looking ahead

October’s developments reflect a life sciences industry continuing to advance through scientific discovery, regulatory progress, strategic investment and a growing commitment to patient-centred care.

From next-generation cancer treatments and promising therapies for autoimmune conditions to innovative vaccine technologies and rare disease research, the month highlighted significant opportunities to address unmet medical needs.

At the same time, the increasing complexity of healthcare systems reinforces the importance of collaboration between regulators, pharmaceutical companies, researchers, healthcare professionals and patient communities.

As the industry continues to evolve, organisations must balance innovation with effective risk management, meaningful patient engagement and clear communication of clinical value.

Advances in artificial intelligence, personalised medicine and research infrastructure will continue to create opportunities, while regulatory expertise and strategic partnerships remain essential for translating scientific discoveries into accessible treatments.

Essjay Solutions will continue to monitor these developments, providing insights into the latest regulatory, clinical, research, healthcare and commercial trends shaping the global life sciences industry.